Pharma ZEE Surl Pharmaceutical Import Profile — Tanzania (DGFT 2022–2026)

Name: Pharma ZEE Surl Pharmaceutical Import Records from India — 2 Products, $300.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pharma ZEE Surl — Pharmaceutical Importer Profile (2026) | 2 Products, $300.0K Trade | TransData Nexus

Pharma ZEE Surl

Pharmaceutical Importer · Tanzania · Antifungals Focus · $300.0K Total Trade · DGFT Verified

Pharma ZEE Surl is a pharmaceutical importer based in Tanzania with a total trade value of $300.0K across 2 products in 2 therapeutic categories. Based on 6 verified import shipments from Indian Customs (DGFT) records, Pharma ZEE Surl is the #1 buyer in 1 product including Tinidazole. Pharma ZEE Surl sources from 1 verified Indian supplier, with Vansh Remedies accounting for 100.0% of imports.

Pharma ZEE Surl — Import Portfolio & Supplier Network

Pharma ZEE Surl import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Pharma ZEE Surl?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vansh Remedies	$1.4M	42	100.0%

Pharma ZEE Surl sources from 1 verified Indian supplier across 14 distinct formulations. The sourcing is highly concentrated — Vansh Remedies accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Pharma ZEE Surl Import?

Formulation	Value	Ships
Tini-van- tinidazole tablets BP 500 MG	$110.5K	3
Ibu-van - ibuprofen tablets BP 400 MG	$103.7K	3
Nyst-van- nystatin suspension 100000	$103.7K	3
Rectovan - anti haemorrhoidal	$103.5K	3
Indo-van - indometacine capsules 25 MG	$103.1K	3
Diclo-van -diclofenac sodium	$103.1K	3
Rhinovan-p - carbocisteine &	$102.9K	3
Stovan ointment - triamciolone	$102.7K	3
Stovan cream - triamciolone acetonide	$102.7K	3
Rhinovan-5 - carbocisteine syrup 5%	$102.5K	3
Rhinovan-2 - carbocisteine syrup 2%	$102.2K	3
Glyco-van - glycerine suppositories	$102.0K	3
Ibu-van+ - ibuprofen & paracetamol	$101.7K	3
Rectovan - anti haemorrhoidal cream	$101.3K	3

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Nystatin	Antifungals	$150.0K	3	0.3%	10
2	Tinidazole	Advanced Antibiotics	$150.0K	3	0.8%	1

Pharma ZEE Surl imports 2 pharmaceutical products across 2 categories into Tanzania totaling $300.0K. The company is the #1 buyer for 1 product: Tinidazole.

Pharma ZEE Surl — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Pharma ZEE Surl is a pharmaceutical importer and buyer based in Tanzania, specializing in the acquisition of finished pharmaceutical formulations from India. The company has engaged in six shipments over the period from 2022 to 2026, with a total import value of $300,000 USD. These imports encompass two primary therapeutic categories: Antifungals and Advanced Antibiotics, each accounting for 50% of the portfolio. The top five products imported include Nystatin and Tinidazole, each valued at $150,000 USD, representing 0.3% and 0.8% market share respectively. Notably, Pharma ZEE Surl is the leading buyer of Tinidazole in the Tanzanian market. The company's sole verified Indian supplier is VANSH REMEDIES, which has provided all 42 shipments, amounting to $1.4 million USD. This indicates a high level of supplier concentration, with a portfolio comprising 14 unique formulations.

2Distribution Network

While specific details about Pharma ZEE Surl's warehouse locations and logistics capabilities are not publicly available, the company's import activities suggest a distribution network that effectively serves the Tanzanian market. The focus on finished pharmaceutical formulations indicates a streamlined supply chain designed to meet the needs of local healthcare providers. The reliance on a single supplier, VANSH REMEDIES, suggests a centralized procurement strategy, potentially facilitating efficient inventory management and distribution processes.

3Industry Role

Pharma ZEE Surl operates as a primary wholesaler in Tanzania's pharmaceutical supply chain. By importing finished pharmaceutical formulations directly from India, the company plays a crucial role in bridging the gap between international manufacturers and local healthcare providers. This position enables Pharma ZEE Surl to supply a range of pharmaceutical products to various stakeholders, including hospitals, clinics, and pharmacies across Tanzania.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Pharma ZEE Surl

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The exclusive sourcing from VANSH REMEDIES indicates a high supplier concentration for Pharma ZEE Surl. This single-source dependency could pose risks, such as supply chain disruptions or pricing volatility. However, the consistent volume of shipments and the substantial total import value suggest a stable and mutually beneficial relationship between Pharma ZEE Surl and VANSH REMEDIES. The strategic choice to concentrate sourcing may also allow for better negotiation terms and streamlined logistics.

2Supply Chain Resilience

Pharma ZEE Surl's supply chain resilience appears robust, given the consistent sourcing from a single supplier, VANSH REMEDIES. The company's focus on finished pharmaceutical formulations indicates a streamlined procurement process. However, the lack of publicly available information on backup suppliers and formulation diversity suggests potential vulnerabilities. To enhance resilience, Pharma ZEE Surl might consider diversifying its supplier base and incorporating additional formulations to mitigate risks associated with over-reliance on a single source.

3Strategic Implications

Importing Pharmaceuticals into Tanzania — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Tanzania

1Regulatory Authority & Framework

The Tanzania Medicines and Medical Devices Authority (TMDA) is the primary regulatory body overseeing the importation and exportation of pharmaceutical products in Tanzania. Established under the Tanzania Medicines and Medical Devices Act, Cap. 219, TMDA is responsible for ensuring the safety, efficacy, and quality of medicines and medical devices. Key legislation governing pharmaceutical imports includes the Pharmaceutical and Poisons Act, which outlines the control of manufacture, sale, import, and export of pharmaceutical products. The registration of pharmaceutical products is mandated under these regulations, requiring importers to obtain appropriate licenses and ensure compliance with established standards.

2Import Licensing & GMP

Importers of pharmaceutical products in Tanzania must obtain a valid import license from TMDA. The application process involves submitting necessary documents and paying the prescribed fees. Importers are also required to register their premises with TMDA and ensure compliance with Good Manufacturing Practice (GMP) standards. GMP certification from recognized authorities, such as the World Health Organization (WHO), is essential for the importation of pharmaceutical products. Additionally, importers must adhere to labeling requirements, including the use of the English language and compliance with TMDA's guidelines. (tmda.go.tz)

Pharma ZEE Surl — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Pharma ZEE Surl's focus on Antifungals and Advanced Antibiotics aligns with the prevalent health challenges in Tanzania, where infectious diseases are a significant concern. The importation of these specific therapeutic areas addresses the market demand for effective treatments, particularly in the context of rising antimicrobial resistance. By concentrating on these categories, Pharma ZEE Surl positions itself to meet critical healthcare needs and contribute to public health outcomes in the region.

2Sourcing Profile

Pharma ZEE Surl's sourcing strategy is centered on generic drugs, primarily sourced from India, a global hub for pharmaceutical manufacturing. The company's preference for finished pharmaceutical formulations indicates a focus on ready-to-market products, facilitating quicker distribution and availability. This approach allows Pharma ZEE Surl to efficiently meet the demand for essential medicines in Tanzania without the complexities associated with raw material procurement and manufacturing.

3Market Positioning

With its importation of finished pharmaceutical formulations, Pharma ZEE Surl serves the wholesale distribution segment of the Tanzanian market. By supplying a range of pharmaceutical products to various stakeholders, including hospitals, clinics, and pharmacies, the company plays a pivotal role in ensuring the availability of essential medicines across the country. This positioning enables Pharma ZEE Surl to influence the pharmaceutical supply chain and contribute to the overall healthcare infrastructure in Tanzania.

Seller's Guide — How to Become a Supplier to Pharma ZEE Surl

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Tanzanian market by partnering with Pharma ZEE Surl. The company's concentrated sourcing strategy indicates a potential openness to diversifying its supplier base, which could lead to increased competition and innovation. Indian exporters can leverage this opportunity by meeting Pharma ZEE Surl's specific product requirements, quality standards, and regulatory compliance to establish a foothold in the Tanzanian pharmaceutical market.

2Requirements & Qualifications

Indian exporters aiming to supply Pharma ZEE Surl and the Tanzanian market must ensure that their products are registered with TMDA and manufactured in facilities compliant with WHO-GMP standards. They must also adhere to TMDA's labeling requirements, including the use of the English language and inclusion of all necessary product information. Additionally, exporters should be prepared to provide all necessary documentation and samples as required by TMDA during the import permit application process. (tmda.go.tz)

3How to Approach

Frequently Asked Questions — Pharma ZEE Surl

What products does Pharma ZEE Surl import from India?

Pharma ZEE Surl imports 2 pharmaceutical products across 2 categories. Top imports: Nystatin ($150.0K), Tinidazole ($150.0K).

Who supplies pharmaceuticals to Pharma ZEE Surl from India?

Pharma ZEE Surl sources from 1 verified Indian suppliers. The primary supplier is Vansh Remedies (100.0% of imports, $1.4M).

What is Pharma ZEE Surl's total pharmaceutical import value?

Pharma ZEE Surl's total pharmaceutical import value from India is $300.0K, based on 6 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Pharma ZEE Surl focus on?

Pharma ZEE Surl imports across 2 categories. The largest: Antifungals (50.0%), Advanced Antibiotics (50.0%).

Get Full Pharma ZEE Surl Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.